Related Experiment Video
Updated: Jun 19, 2026
Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
Published on: April 8, 2013
Use of aldosterone antagonists in heart failure
Nancy M Albert1, Clyde W Yancy, Li Liang
1Nursing Institute and Kaufman Center for Heart Failure, Cleveland Clinic, Cleveland, Ohio, USA. albertn@ccf.org
Insights
Less than one-third of eligible heart failure patients received guideline-recommended aldosterone antagonist therapy. Prescription rates increased modestly, but significant hospital variation existed, while inappropriate use remained low.
Area of Science:
- Cardiology
- Pharmacology
- Health Services Research
Background:
- Aldosterone antagonists are recommended for moderate to severe heart failure (HF) with systolic dysfunction.
- Prior studies indicate both underuse in eligible patients and overuse in harmful settings.
Purpose of the Study:
- To examine aldosterone antagonist prescription patterns in hospitalized heart failure patients.
- To assess prescription rates based on HF management guideline and appropriateness criteria.
- To analyze trends in aldosterone antagonist use over time.
Main Methods:
- Observational analysis of 43,625 hospitalized HF patients from January 2005 to December 2007.
- Utilized data from the Get With The Guidelines-HF quality improvement registry.
- Examined prescription rates and predictors of aldosterone antagonist use based on guideline criteria.
Main Results:
- Only 32.5% of 12,565 eligible patients received an aldosterone antagonist at discharge.
- Prescription rates increased modestly from 28% to 34% over the study period.
- Significant hospital-level variation in use (0%-90.6%) was observed; inappropriate use was low.
Conclusions:
- Less than one-third of eligible hospitalized heart failure patients received guideline-recommended aldosterone antagonist therapy.
- Aldosterone antagonist use among patients with contraindications was low.
- Significant disparities in guideline-recommended therapy exist.
Context:
Aldosterone antagonists are recommended for patients with moderate to severe heart failure (HF) and systolic dysfunction. Prior studies suggest underuse of aldosterone antagonists in eligible patients as well as overuse in settings in which therapy may be harmful.
Objective:
To examine aldosterone antagonist prescription based on HF management guideline criteria, investigator-defined appropriateness criteria, and trends over time in patients hospitalized with heart failure.
Design, Setting, And Patients:
Observational analysis of 43,625 patients admitted with HF and discharged home from 241 hospitals participating in the Get With The Guidelines-HF quality improvement registry between January 2005 and December 2007.
Main Outcome Measures:
Prescription and predictors of use of aldosterone antagonists, based on guideline criteria.
Results:
Among 12,565 patients eligible for aldosterone antagonist therapy, 4087 (32.5%) received an aldosterone antagonist at discharge, and treatment increased modestly from 28% to 34% over the study period. There was also wide variation in aldosterone antagonist use among hospitals (0%-90.6%). Aldosterone antagonist use in eligible patients was associated with younger age (adjusted odds ratio [OR], 0.85; 95% confidence interval [CI], 0.82-0.88), African American race/ethnicity (adjusted OR, 1.17; 95% CI, 1.04-1.32), lower systolic blood pressure (adjusted OR, 0.94; 95% CI, 0.92-0.95), history of implantable cardioverter-defibrillator use (adjusted OR, 1.51; 95% CI, 1.34-1.69), depression (adjusted OR, 1.15; 95% CI, 1.01-1.30), alcohol use (adjusted OR, 1.23; 95% CI, 1.02-1.50), and pacemaker implantation (adjusted OR, 1.21; 95% CI, 1.06-1.38), and with having no history of renal insufficiency (adjusted OR, 0.85; 95% CI, 0.75-0.96). Applying serum creatinine and potassium appropriateness criteria, inappropriate and potentially inappropriate use of aldosterone antagonist therapy was low and did not change over the 3-year study period.
Conclusions:
Less than one-third of eligible patients hospitalized for HF and participating in a quality improvement registry received HF guideline-recommended aldosterone antagonist therapy. Use of aldosterone antagonist therapy among patients with documented contraindications was low.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:22Heart Failure Drugs: Diuretics
01:22Heart Failure Drugs: β-Blockers
01:30Heart Failure V: Medical Management
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
01:25Antihypertensive Drugs: Direct Renin Inhibitors